Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Pharma Chiefs To Helm Brexit Steering Committee

Executive Summary

Sir Andrew Witty and Pascal Soriot, CEOs of GlaxoSmithKline and AstraZeneca, respectively, are to co-chair a new steering group along with George Freeman, the UK's life sciences minister. The group will address the challenges posed to the sector by the UK's decision to withdraw from the EU.


Related Content

New Barrier For UK’s Brexit Plans; Industry Looks For Potential Opportunities
Spanner In Works For UK Gvn’t’s Brexit Plans; Industry Looks To Ongoing Talks with Ministers
Spanner In Works For UK Gov’t’s Brexit Plans; Industry Looks To Ongoing Talks With Ministers
‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System
UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles
AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
Brexit Talks Must Prioritize Patient Access, Avoid Regulatory Divergence, Says EFPIA
Brexit: The Implications For Biotech Fundraising And Investment
UK Bioscience in Frontline of EU Brexit Revenge
The Brexit Timebomb: Expect Effects On Drug Regulation, IP, Research And Trade


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts